Skip to main content

Table 3 Baseline characteristics of final study cohort

From: Cost-effectiveness analysis of imaging surveillance in stage II and III extremity soft tissue sarcoma: an Australian perspective

Patients demographics

Total

PMC

RAH

POW

(N = 133)

(N = 92)

(N = 22)

(N = 19)

Mean age at diagnosis, years

55

53

61

63

Age range, years

19–90

19–90

19–90

27–80

Female to male

01:01.2

01:01.5

1.1:1

02:01

Stage

 II

53 (40%)

40

6

7

 III

77 (58%)

49

20

8

 Unknowna

3 (2%)

3

0

0

Sarcoma subtypes

 Undifferentiated pleomorphic sarcoma

53

39

8

6

 Liposarcoma

26

15

5

6

 Synovial sarcoma

19

18

1

0

 Leiomyosarcoma

12

6

4

2

 Other

23

14

4

5

Treatment breakdown

 Surgery alone

30

4

14

12

 Surgery and radiotherapyb

95

86

7

2

 Surgery and chemotherapyc

0

0

0

0

 Surgery, radiotherapy, and chemotherapyd

8

2

1

5

  1. aLocalised soft tissue sarcomas with no evidence of metastasis and resectable but missing staging information
  2. bRadiotherapy delivered in neoadjuvant or adjuvant setting
  3. cChemotherapy delivered in neoadjuvant or adjuvant setting
  4. dRadiotherapy and chemotherapy delivered in neoadjuvant or adjuvant setting, concurrently or in sequence